Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 9/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055093 | 0.89 | SMN1; SMN2 (0.46) | PRKAA2SLC6A7SMN1; SMN2 | |
| SCHEMBL2002975 | 0.87 | HSP90AA1 (0.57) | L3MBTL1MEN1KMT2ATACR3 | |
| SCHEMBL2009579 | 0.87 | CNR1 (0.53) | SLC6A7L3MBTL1MEN1KMT2ATACR3 | |
| SCHEMBL2007046 | 0.87 | CNR1 (0.53) | SLC6A7L3MBTL1MEN1KMT2ATACR3 | |
| SCHEMBL2008943 | 0.86 | FAAH (0.52) | SLC6A7L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2008436 | 0.86 | FAAH (0.52) | PRKAA2SLC6A7L3MBTL1MEN1KMT2A | |
| SCHEMBL2002840 | 0.84 | MEN1 (0.47) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3066941 | 0.84 | CNR1 (0.45) | SLC6A7L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2012084 | 0.83 | CNR1 (0.59) | L3MBTL1MEN1KMT2ATACR3SMN1; SMN2 | |
| SCHEMBL2011725 | 0.83 | HSP90AA1 (0.53) | MEN1KMT2ATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | PRKAA2 3535/4885PRKAB2 1802/4885PRKAG1 2241/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | PRKAA2 3535/4885PRKAB2 1802/4885PRKAG1 2241/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | PRKAA2 3535/4885PRKAB2 1802/4885PRKAG1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.